Ridgetech (RDGT)
NASDAQ:RDGT
Top Page
Ridgetech
(NASDAQ:RDGT)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.10
▼(-96.20% Downside)
Action:UpgradedDate:03/26/26
The score is driven primarily by weak financial performance (revenue decline, ongoing operating losses, and historically inconsistent cash generation) and bearish technicals (below key moving averages with negative MACD). Partial support comes from improving 2025 metrics—positive net income, positive operating/free cash flow, and reduced debt—but these improvements need to prove durable.
Positive Factors
Balance sheet improvement (2025)
Material debt reduction and higher equity in 2025 meaningfully lower financial risk for a thin-margin distributor. This improves liquidity and covenant headroom, increasing runway for operational fixes or strategic investments if management sustains deleveraging and avoids cyclical refinancing stress.
Negative Factors
Revenue volatility & decline
An ~18% revenue drop following volatile top-line performance highlights demand instability or market share pressure. For a distributor with low operating leverage, persistent revenue weakness undermines gross margin absorption and makes multi-year recovery harder without clear, repeatable revenue drivers.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet improvement (2025)
Material debt reduction and higher equity in 2025 meaningfully lower financial risk for a thin-margin distributor. This improves liquidity and covenant headroom, increasing runway for operational fixes or strategic investments if management sustains deleveraging and avoids cyclical refinancing stress.
Read all positive factors
Ridgetech (RDGT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.94M
Dividend YieldN/A
Average Volume (3M)35.98K
Price to Earnings (P/E)―
Beta (1Y)-0.16
Revenue Growth-22.37%
EPS Growth63.14%
CountryUS
Employees939
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)N/A
Shares Outstanding18,285,639
10 Day Avg. Volume73,880
30 Day Avg. Volume35,985
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.27
Price to Sales (P/S)0.03
P/FCF Ratio-1.02
Enterprise Value/Market Cap-4.52
Enterprise Value/Revenue-0.08
Enterprise Value/Gross Profit1.06
Enterprise Value/Ebitda-1.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ridgetech Business Overview & Revenue Model
Company Description
Ridgetech Inc operates as a holding company. The Company, through its subsidiaries, wholesales, distributes, and retails pharmaceutical and other healthcare products....
Ridgetech Financial Statement Overview
Summary
Income Statement
41
Neutral
Balance Sheet
38
Negative
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 111.62M | 119.97M | 154.54M | 148.81M | 164.39M | 133.13M |
| Gross Profit | -8.29M | 3.84M | 31.11M | 34.28M | 36.52M | 29.24M |
| EBITDA | 6.66M | 4.98M | 1.23M | -19.96M | -579.93K | -6.14M |
| Net Income | 12.41M | 10.19M | -4.23M | -21.14M | -3.19M | -8.12M |
Balance Sheet | ||||||
| Total Assets | 61.39M | 64.48M | 95.06M | 90.97M | 106.38M | 106.31M |
| Cash, Cash Equivalents and Short-Term Investments | 13.94M | 12.78M | 20.15M | 18.81M | 18.46M | 22.14M |
| Total Debt | 4.66M | 10.39M | 43.22M | 42.16M | 48.67M | 46.78M |
| Total Liabilities | 31.61M | 34.85M | 80.76M | 74.30M | 83.65M | 81.91M |
| Stockholders Equity | 29.78M | 29.64M | 15.64M | 18.01M | 24.09M | 25.74M |
Cash Flow | ||||||
| Free Cash Flow | 5.35M | 632.50K | -4.08M | -3.60M | -5.69M | -666.47K |
| Operating Cash Flow | 5.35M | 1.25M | -3.16M | -3.28M | -5.39M | -62.29K |
| Investing Cash Flow | 0.00 | -18.14M | -2.04M | -316.10K | -306.14K | -2.00M |
| Financing Cash Flow | -5.87M | 1.51M | 8.00M | 2.37M | 4.84M | 3.08M |
Ridgetech Technical Analysis
Negative
2.66
Price Trends
1.89
Negative
2.63
Negative
1.96
Negative
Market Momentum
-0.10
Positive
33.30
Neutral
22.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RDGT, the sentiment is Negative. The current price of 2.66 is above the 20-day moving average (MA) of 1.82, above the 50-day MA of 1.89, and above the 200-day MA of 1.96, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 33.30 is Neutral, neither overbought nor oversold. The STOCH value of 22.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RDGT.
Ridgetech Risk Analysis
Ridgetech disclosed 58 risk factors in its most recent earnings report. Ridgetech reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
HJ Group is subject to restrictions on making payments to us. Q1, 2023
Ridgetech Peers Comparison
UnderperformOutperform
Sector (51)
RDGT
Ridgetech
0.11
-1.07
-91.02%
GEG
Great Elm Group
1.88
-0.01
-0.53%
SNYR
Synergy CHC
1.17
-2.04
-63.55%
WGRX
Wellgistics Health Inc
0.12
-3.75
-96.80%
Ridgetech Corporate Events
Ridgetech Posts Flat Half-Year Revenue but Slightly Stronger Balance Sheet
Mar 5, 2026
Ridgetech, Inc. has furnished its unaudited interim financial results for the six months ended Sept. 30, 2025, reporting essentially flat revenue of $62.8 million compared with the same period in 2024 and a slight increase in gross profit to $2.46...
Ridgetech Launches $200 Million At-the-Market Share Offering Program
Dec 30, 2025
On December 29, 2025, Ridgetech, Inc. entered into a sales agreement with AC Sunshine Securities LLC to establish an at-the-market equity offering program allowing the company to issue and sell up to $200 million of its ordinary shares from time t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.